<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003151</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-20961</org_study_id>
    <secondary_id>EORTC-20961</secondary_id>
    <secondary_id>CRC-EORTC-20961</secondary_id>
    <secondary_id>HOVON-33</secondary_id>
    <nct_id>NCT00003151</nct_id>
  </id_info>
  <brief_title>Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma</brief_title>
  <official_title>A Phase II Clinical Trial of Anti-Helicobacter Pylori Treatment in Endoscopically Diagnosed Low-Grade Localized Gastric Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated
      with gastric lymphoma.

      PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients
      with low grade gastric lymphoma that has not been previously treated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the rate of eradication of Helicobacter pylori using omeprazole,
      colloidal bismuth subcitrate, tetracycline, and metronidazole in patients with low grade
      gastric lymphoma. II. Determine the macroscopic/endoscopic and microscopic healing/remission
      rate after eradication of Helicobacter pylori in this patient population. III. Determine the
      natural history of low grade gastric lymphoma after eradication of Helicobacter pylori.

      OUTLINE: This is a nonrandomized, open label, multicenter study. Patients receive oral
      omeprazole bid on days 1-10, oral bismuth subcitrate and oral tetracycline qid on days 4-10,
      and oral metronidazole tid on days 4-10. Patients are evaluated at 8 weeks. Patients who
      experience complete remission and are H. pylori negative proceed to follow up. Patients with
      complete remission or no change but who are H. pylori positive proceed to a second course of
      therapy with the previous schedule or with omeprazole bid, amoxicillin qid, and
      clarithromycin tid for 14 days. Patients who experience no change but are H. pylori negative
      are followed at 6 and 9 months and restaged. Patients are followed at 6, 9, 12, 18, and 24
      months, then annually thereafter.

      PROJECTED ACCRUAL: Approximately 60-96 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1997</start_date>
  <primary_completion_date type="Actual">October 1998</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>bismuth subcitrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracycline hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven, previously untreated, low grade gastric
        lymphoma Clinical stage I and II1 No bulky disease No high grade component (grade 5 and 4,
        if monoclonality proven, allowed) Documented presence/absence of H. pylori infection
        Measurable and/or evaluable disease

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:
        Not pregnant or lactating Fertile patients must use effective contraception No prior or
        concurrent malignancies unless: At least 1 year remission Low risk or recurrence No prior
        gastric malignancy No nonmalignant disease causing poor medical risk No allergy to
        omeprazole

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the abdomen
        Surgery: No prior gastric surgery except simple closure of perforated ulcer with or without
        wedge excision of the ulcer Other: No prior therapy for gastric lymphoma At least 30 days
        since experimental therapy No other concurrent experimental therapy At least 30 days since
        antibiotics with activity against H. pylori
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice P. Carde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John W. Sweetenham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <state>England</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Birmingham N.H.S. Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hampstead, London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital School of Medicine</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's, King's and St. Thomas' Hospitals Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 ONN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlesex Hospital- Meyerstein Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1N 8AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>L63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle General Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal South Hants Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO14 0YG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2004</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Bismuth tripotassium dicitrate</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

